Cite
HARVARD Citation
Powles, T. et al. (2015). Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].